Apexlab: From The U.S. To Canada: High-Quality Psilocybin API Gets Green Light For Import

Canadian mental healthcare biopharma company Apex Labs, Ltd. received approval for its new US-based supplier of Good Manufacturing Practices (GMP)-compliant psilocybin Active Pharmaceutical Ingredient (API.) The company is currently conducting several large-scale, "statistically-powered" multicenter micro-and-macro dose Phase 2b psilocybin clinical trials, producing the synthetic capsules through its primary Canadian-based supplier and now adding the U.S. API provider. The new permit, which allows Apex to ship the drug across the border, has been granted by Health Canada (via a Clinical Trial Application amendment) as well as the DEA and U.S. customs. Apex co-founder and CSO Dr. Orion Lekos called the approval "a large step forward" for the company's drug ...Full story available on Benzinga.com